Navigation Links
Ikaria® CEO Daniel Tasse Elected to PhRMA Board of Directors
Date:9/22/2011

HAMPTON, N.J., Sept. 22, 2011 /PRNewswire/ -- Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients in the hospital and ICU settings, today announced that its Chairman and CEO Daniel Tasse has been elected to the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA).

Headquartered in Washington, D.C., PhRMA represents the country's leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier and more productive lives.

In addition to his membership on the 31-person board, Mr. Tasse will serve on the PhRMA Rare Disease and Emerging Company Committees.  Mr. Tasse brings to these positions an extensive track record in the healthcare industry with a wealth of knowledge and passion for critical care, in particular.

"I'm honored to join this prestigious group of industry leaders and innovators," said Mr. Tasse. "Through my new position on PhRMA's Board of Directors, I look forward to helping to move forward policies that will advance the pharmaceutical industry and continue to benefit patients during this important time for our industry and our economy."

Mr. Tasse also is a member of the Board of Directors and Health Section Governing Board of the Biotechnology Industry Organization (BIO), where he participates on the bioethics, regulatory environment and reimbursement committees.  Additionally, he is a member of the Healthcare Leadership Council and is a member of the Board of Directors of the Roundtable on Critical Care Policy.

Prior to joining Ikaria, Mr. Tasse served as General Manager of the Pharmaceutical Technologies Business Unit of Baxter International.  Earlier in his career, Mr. Tasse held a number of Senior Management positions at GlaxoSmithKline, including that of Vice President and Regional Director for AustralAsia.  He earned a B.S. in Biochemistry from the University of Montreal.

About Ikaria Inc.Ikaria, Inc. is a critical care company focused on developing and commercializing innovative therapies designed to address the significant needs of critically ill patients in the hospital and ICU settings. The company's lead product is INOMAX® (nitric oxide) for inhalation, the only FDA-approved drug for the treatment of hypoxic respiratory failure associated with pulmonary hypertension in term and near-term infants. It is offered through the INOMAX therapy package, an all-inclusive offering of drug product, drug-delivery system, on-site training and 24/7/365 technical assistance and support. The INOMAX therapy package also is marketed in Puerto Rico, Canada, Australia, Mexico and Japan. The company is pursuing a number of new indications with INOMAX. Ikaria's late stage pipeline is also comprised of LUCASSIN® (terlipressin), a potential treatment for hepatorenal syndrome Type 1; as well as IK-5001, a potential treatment for preventing cardiac remodeling and subsequent congestive heart failure following acute myocardial infarction. Ikaria is headquartered in Hampton, NJ, with research facilities in Seattle, WA and Madison, WI, and manufacturing facilities in Port Allen, LA and Madison, WI.  Please visit www.ikaria.com. Company Contact:Media Contacts:Samina Bari

Tiberend Strategic Advisors, Inc.Ikaria, Inc.

(212) 827-0020(908) 238-6372

Claire Sojdasamina.bari@ikaria.com

csojda@tiberend.com
'/>"/>

SOURCE Ikaria, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ikaria® Names New Chief Financial Officer
2. Ikaria® to Present at 31st Annual Cowen and Company Healthcare Conference
3. Ikaria® Launches Next-Generation Drug-Delivery System
4. Ikaria® to Present at 2011 Wedbush Life Sciences Management Access Conference
5. Daniel K. Spiegelman Elected to Board of Directors of Omeros
6. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
7. Governor Daniels Signs Into Law Electronic Tracking Bill
8. Daniels Jumps to No. 2 in Medical Waste Disposal Industry
9. Daniels Sharpsmart Expands U.S. Presence With New Pennsylvania Facility
10. Daniels Sharpsmart Expands U.S. Presence With New Facility in Midwest
11. Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/13/2017)...   OrthoAtlanta has been named the official orthopedic ... (AFHC) for the 2018 College Football Playoff (CFP) National Championship ... Stadium in Atlanta, Georgia . OrthoAtlanta is ... campaign, participating in many activities leading up to, and including ... ...
(Date:9/12/2017)... Sept. 12, 2017  ValGenesis Inc., the global ... is pleased to announce the appointment of Dr. ... its Board of Directors and Chairman of Advisory ... life science companies to manage their entire validation ... paper in this process. Furthermore, ValGenesis VLMS enables ...
(Date:9/9/2017)... 2017  Eli Lilly and Company (NYSE: ... data for lasmiditan, an investigational, oral, first-in-class molecule for ... improvements compared to placebo in the Phase 3 SPARTAN ... 18th Congress of the International Headache Society (IHC) in ... presented today demonstrate lasmiditan,s potential to reduce pain and ...
Breaking Medicine Technology:
(Date:9/19/2017)... ... 2017 , ... The Davidson Institute for Talent Development will ... 27 at a reception in Washington D.C. The recipients received $50,000, $25,000 and ... “I am honored to be a Davidson Fellow Laureate,” said Rishab Gargeya, a ...
(Date:9/19/2017)... Brook, IL (PRWEB) , ... September 19, 2017 ... ... are significantly and positively linked to the Certified Emergency Nurse (CEN®) certification ... for Emergency Nursing (BCEN). The value of certification study, conducted by the Human ...
(Date:9/18/2017)... (PRWEB) , ... September 19, 2017 , ... ... Asia Pacific’s protein ingredient market , expected to grow at the fastest CAGR ... Sullivan sharing the ‘Global Food Protein Trends & Growth Opportunities in Asia’ – ...
(Date:9/18/2017)... ... September 18, 2017 , ... ... the finance role on the executive team adding a Chief Financial Officer following ... independent company. This expansion will support the strategic growth strategy Aegis has defined ...
(Date:9/18/2017)... Fort Lee, NJ (PRWEB) , ... September 18, 2017 , ... ... state’s history, CareOne, a New jersey based company, has launched an aid effort focused ... Irma as it battered the state over two days and left thousands homeless and ...
Breaking Medicine News(10 mins):